Xencor Corp - XNCR Net earnings per share for the last four quarters

Xencor, Inc. (XNCR) profit dynamics are based on the development of antibodies to combat oncology and autoimmune pathologies. The YoY EPS growth rate (trailing 12 months) illustrates the impact of the protein engineering platform for pharma behemoths, as well as the stability of royalties from licensees. The current 11.30 indicator shows the value of this parameter, confirming the resilience of the company's operating model within the immuno-oncology sector.
XNCR (Xencor): analytical breakdowns and indicator data

Amidst a fierce battle against industry behemoths to establish itself as the standard in cancer immunotherapy, Xencor, Inc. must demonstrate high efficiency in capitalizing on its developments. The trailing twelve-month (TTM) earnings per share dynamics compared to last year allow for a real-time assessment of business profitability relative to the sector, which is clearly reflected in the annual EPS growth rate (ttm).